Vijaya Diagnostic Centre's Quality Grade Revised Amid Strong Financial Performance Metrics

Vijaya Diagnostic Centre has recently undergone an evaluation revision, reflecting its current standing within the healthcare services sector. The company has demonstrated a sales growth rate of 13.10% over the past five years, alongside an EBIT growth of 7.27%. Its EBIT to interest ratio averages at 7.68, indicating a solid capacity to cover interest expenses. The company maintains a low debt to EBITDA ratio of 1.30 and a net debt to equity ratio of 0.03, showcasing a strong balance sheet.
In terms of operational efficiency, Vijaya Diagnostic Centre has a sales to capital employed ratio of 0.51 and a tax ratio of 25.58%. The dividend payout ratio stands at 14.35%, with no pledged shares, reflecting a stable financial position. Institutional holding is notable at 43.61%, while the return on capital employed (ROCE) averages 22.99% and return on equity (ROE) averages 13.89%.

When compared to its peers, Vijaya Diagnostic Centre's performance is relatively strong, particularly against companies like Aster DM Healthcare and Health.Global, which are positioned lower in the quality spectrum. In contrast, competitors such as Dr. Lal Pathlabs and Krishna Institute show stronger metrics, highlighting the competitive landscape in which Vijaya operates.